請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57182
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Jiuan Shen) | |
dc.contributor.author | Chia-Hui Lin | en |
dc.contributor.author | 林佳慧 | zh_TW |
dc.date.accessioned | 2021-06-16T06:37:08Z | - |
dc.date.available | 2014-10-20 | |
dc.date.copyright | 2014-10-20 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-07-31 | |
dc.identifier.citation | 1. Iung B. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-43.
2. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. The Lancet 2006;368:1005-11. 3. Smith SA, Waggoner AD, de las Fuentes L, et al. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J Am Soc Echocardiogr 2009;22:883-9. 4. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9. 5. Bhattacharyya S, Schapira AH, Mikhailidis DP, et al. Drug-induced fibrotic valvular heart disease. Lancet 2009;374:577-85. 6. Rothman RB, Redmon JB, Raatz SK, et al. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 2000;85:913-5. 7. Cosyns B, Droogmans S, Rosenhek R, et al. Drug-induced valvular heart disease. Heart 2013;99:7-12. 8. Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 2013;106:333-9. 9. Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006;113:81-9. 10. Levy RJ. Serotonin transporter mechanisms and cardiac disease. Circulation 2006;113:2-4. 11. Wu CS, Shau WY, Chan HY, et al. Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009. Pharmacoepidemiol Drug Saf 2012;21:980-8. 12. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802. 13. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014. 14. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-96. 15. Administration US Food and Drug Administration. FDA analysis of cardiac valvular dysfunction with use of appetite suppressants. Washington, DC: US Food and Drug Administration 1997. 16. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999;83:897-902. 17. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46. 18. American College of Cardiology/American Heart Association Task Force on Practice G, Society of Cardiovascular A, Society for Cardiovascular A, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-231. 19. Serratrice J, Disdier P, Habib G, et al. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002;10:334-6. 20. Kim JY, Chung EJ, Park SW, et al. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006;21:1261-4. 21. Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC. Bromocriptine use and the risk of valvular heart disease. Mov Disord 2009;24:344-9. 22. Rasmussen VG, Ostergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord 2011;26:801-6. 23. Robiolio PA, Rigolin VH,, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790. 24. Elangbam CS, Job LE, Zadrozny LM, et al. 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 2008;60:253-62. 25. Rothman RB, Baumann MH, Savage JE, et al. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. Circulation 2000;102:2836-41. 26. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29:80-6. 27. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003;108:32-6. 28. Teter CT, Kando JC, Wells BG. Major Depressive disorder. In: Dipiro JT TR, Yee GC, Matzke GR, Wells BG, Posey LM ed. Pharmacotherapy: A Pathophysiologic Approach 8th ed: McGraw-Hill Companies; 2010:1173-90. 29. Lapi F, Nicotra F, Scotti L, et al. Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database. Br J Clin Pharmacol 2012;74:536-44. 30. Mast ST, Gersing KR, Anstrom KJ, et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001;87:989-93: a4. 31. Tribouilloy C, Marechaux S, Jobic Y, et al. Frequency of drug-induced valvular heart disease in patients previously exposed to benfluorex: a multicentre prospective study. Eur Heart J 2013. 32. Kuo CC, Chien IC, Lin CH, et al. Prevalence, correlates, and disease patterns of antidepressant use in Taiwan. Compr Psychiatry 2011;52:662-9. 33. Melton ST and Kirkwood CK. Anxiety disorders I: generalized anxiety, panic, and social anxiety disorders. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM ed. Pharmacotherapy: A Pathophysiologic Approach 8th ed McGraw-Hill Companies; 2010:1209-27. 34. Rush AJ and Kupfer DJ. Strategies and tactics in the treatment of depression. In: Gabbard GO ed. Treatment of psychiatric disorders. 3rd ed. Washington, D.C.: American Psychiatric Press, 2001:1417-39. 35. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157:1-45. 36. Geddes JR, Carney SM, Davies C, et al. . Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-61. 37. Mann JJ. The medical management of depression. N Engl J Med 2005;353:1819-34. 38. Marechaux S, Jeu A, Jobic Y, et al. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: A multicentre study. Arch Cardiovasc Dis 2013;106:349-56. 39. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. 40. Goldberg D, Lewis J, Halpern S, et al. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 2012;21:765-9. 41. Chen G, Khan N, Walker R, et al. Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract 2010;89:189-95. 42. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24. 43. Jollis JG, Landolfo CK, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-7. 44. Wu CS, Shau WY, Chan HY, et al. Persistence of antidepressant treatment for depressive disorder in Taiwan. Gen Hosp Psychiatry 2013;35:279-85. 45. Serretti A, Benedetti F, Zanardi R, et al. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1074-84. 46. Finley PR and Lee KC. Mood Disorders I: Major Depressive Disorders. In: Koda-Kimble MA YL, Kradjan WA, Guglielmo BJ, Alldredge BK ed. Applied therapeutics: The Clinical Use of Drugs 10th edition: Lippincott Williams & Wilkins; 2012:1949-82. 47. Drug information. In: UpToDate, Basow, DS (Ed), UpToDate,Waltham, MA, 2012. (cited: 2014/07/17), 48. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55. 49. Huang CJ, Hsieh MH, Hou WH, et al. Depression, antidepressants, and the risk of coronary heart disease: A population-based cohort study. Int J Cardiol 2013;168:4711-6. 50. Redfield MM, Nicholson WJ, Edwards WD, et al. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2. 51. Trifiro G. Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia: A Multi-Country, Nested Case-Control Study. Drug Saf 2012;35 159-71. 52. Oeda T, Masaki M, Yamamoto K, et al. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. J Neural Transm 2009;116:171-8. 53. 李佩芬. 多巴胺促效劑之處方型態分析及其對巴金森氏病病人心臟瓣膜病變的影響. 台北: 國立臺灣大學; 2008. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57182 | - |
dc.description.abstract | 研究背景
已知藥品引發的心臟瓣膜疾病之致病機轉可能與血清素(serotonin)濃度、受體(receptor)、運輸體(transporter)相關,如serotonin、fenfluramine及pergolide等,而抗憂鬱藥品其藥理機轉也與serotonin有關,然而之前文獻並沒有發現抗憂鬱藥品與心臟瓣膜疾病(valvular heart disease; VHD)之間的相關性。除研究方法及族群不同外,目前缺乏心臟瓣膜閉鎖不全(cardiac-valve regurgitation;CVR)之International Classification of Diseases-9th edition-Clinical Modification codes (ICD-9-CM code)編碼確效研究,因此,利用臺灣健康保險資料庫(National Health Insurance Research Database;NHIRD)來進行VHD之研究。 研究目的 本研究首先進行住院與門診病人之ICD-9-CM code編碼與CVR之確效研究,以確認VHD病例設定條件。其次,利用臺灣健康保險資料庫探討華人族群抗憂鬱藥品之使用與VHD的相關性。 研究方法 本研究分兩大部分,第一部分,利用2007至2011年臺大醫院住院及門診病人之病歷資料,篩選符合病例條件之住院或門診病人。進一步確認心臟超音波報告中CVR之嚴重程度,將至少有一瓣膜CVR大於等於中度之病人視為確認病例,並計算陽性預測值(positive predictive value;PPV)。第二部分,利用1999至2011年健保資料庫2000、2005、2010之百萬承保歸人檔(約300萬人)建立嵌入型病例對照研究。先排除在1999至2001曾使用抗憂鬱藥品之病人後,收錄2002至2010年大於等於20歲至少使用三次抗憂鬱藥品之病人,並且將第一次使用抗憂鬱藥品日期設定為cohort entry date。排除在cohort entry date前一年曾有VHD、相關病因與可疑藥品之病人後,剩下的人進入研究世代。在研究世代中,篩選出在2002至2011年符合VHD條件之住院病人定義為病例,並且將第一次符合VHD的住院日期定義為index date。排除開始用藥後90天內發生VHD之病例病人,剩下之病例病人以1:4的比例與未發生心臟瓣膜疾病之抗憂鬱藥品使用者,進行年齡、性別、cohort entry date之配對,得到病例組與對照組。分析事件前三年內兩組抗憂鬱藥品的使用狀況,主要分析為將所有抗憂鬱藥品視為一個類別,暴露變項包含使用時序、累積時間、累積劑量以及最後一劑每日劑量;次要分析則依照藥理特性、對serotonin transporter親和力,以及單獨抗憂鬱藥品進行分類。利用 conditional logistic regression進行odds ratio的預測並校正干擾因子,以評估抗憂鬱藥品與VHD之相關性。 研究結果 住院與門診病人之ICD-9-CM code編碼確效研究結果不同,住院病人之PPV高達84.5%,相較之下,門診病人只有33.7%,因此只納入住院病人為病例組。收錄研究族群154,416人,排除14,824人,最後有139,592人進入到研究世代。研究世代中有1,792人符合病例條件,進一步排除從第一次使用抗憂鬱藥品到發生心臟瓣膜疾病小於90天之133名病人,剩下病人經過配對得病例組1,618人與對照組6,742人。結果顯示,主要分析中整體抗憂鬱藥品之使用者,相較於三年內未使用者,與心臟瓣膜疾病之發生不存在顯著相關性(adjusted odds ratio[aOR] 1.05; 95% confidence interval[CI] 0.89-1.23)。另外,累積時間、累積劑量與最後一劑每日劑量亦皆無發現兩者之間的關係性。但是,次要分析則發現在trazodone(aOR 1.26 [1.00-1.59])、imipramine(aOR 1.29 [1.03-1.62])、citalopram(aOR 1.70 [1.06-2.72])、duloxetine(aOR 2.41 [1.11-5.25])之current user與bupropion(aOR 2.87 [1.09-7.56])之recent user有看到顯著增加心臟瓣膜疾病之發生風險。 結論 整體而言,本研究並未發現整體抗憂鬱藥品與心臟瓣膜疾病之相關性,但是值得注意的是,半年內曾經暴露過citalopram、imipramine、duloxetine的患者,以及在半年到一年內曾經暴露過bupropion的患者,相較於三年內未使用抗憂鬱藥品者,可能會增加1.26至2.87倍心臟瓣膜疾病之發生機率。 | zh_TW |
dc.description.abstract | Background Concentration, receptor, transporter of serotonin may involve in mechanisms of drug induced valvular heart disease such as serotonin, fenfluramine, pergolide and so on. Additionally, pharmacologic mechanism of antidepressants are related to serotonin. Nevertheless, no clinical study shows a potential link between use of antidepressants and risk of valvular heart disease (VHD). In addition to different study method and population, the validation of International Classification of Diseases-9th edition-Clinical Modification codes (ICD-9-CM codes) for cardiac-valve regurgitation (CVR) has never been done to study VHD by Taiwan’s National Health Insurance Research Database (NHIRD).
Objective First, to determine the definition of VHD, we conducted two validations of ICD-9-CM codes for inpatients and outpatients with CVR, respectively. Second, we used NHIRD to evaluate the association between use of antidepressants and VHD among Chinese population. Methods Our study was divided into two parts. In the first part, we requested inpatients’ and outpatients’ medical information from National Taiwan University Hospital and identified patients who met case definition during 2007-2011. The echocardiographic reports were reviewed to confirm the severity of CVR. Potential cases with at least one cardiac valve of moderate regurgitation were defined as confirmed cases and positive predictive value (PPV) were calculated. In the second part, a nested case-control study using 2000, 2005, 2010 Longitudinal health insurance database during 1999-2011 as study resource (covering about a population of 3 millions) was conducted. After excluding patients who used antidepressants in 1999 to 2001, we identified patients aged over 20 years with at least 3 prescriptions of antidepressants during 2002-2010. The cohort entry date was the date of the first prescription of antidepressants. Nevertheless, patients who were diagnosed with VHD or related etiologies, or who used drugs that potential causing DIVHD within 1 year before the cohort entry date were excluded. Among study population, we identified inpatients who first hospitalized with incident VHD during 2002-2011 as cases and the date was defined as index date. We further excluded cases with VHD 90 days after the first use of antidepressants. The cases were matched with 4 controls by age, sex and cohort entry date. All prescriptions of antidepressants 3 year before index date were included. In primary analysis, different type of antidepressants were considered as one group and exposure assessment included timing of use, cumulative duration, cumulative dose and last daily dose. In secondary analyses, we further classified antidepressants by type of antidepressants, affinity for serotonin transporter and individual antidepressants. Conditional logistic regression models were used to estimate odds ratio of VHD associated with use of antidepressants. Results The validity of ICD-9-CM code for inpatients with CVR was distinct from outpatients with CVR. The PPV of inpatients was as high as 84.5%. In contrast, the PPV of outpatients was only 33.7%. Therefore, definition of cases was decided to include inpatients solely. In the study period, 154,416 patients met the inclusion criteria. After excluding 14,824 patients, 139,592 patients served as the study population. Among study population, we identified 1,792 inpatients who met case definition and further excluded 133 cases with days between cohort entry date and index date less than 90 days. After matching, 1,618 and 6,742 were the cases and controls, respectively. In primary analysis, users of all antidepressants were not associated with risk of VHD (adjusted odds ratio [aOR] 1.05; 95% confidence interval [CI] 0.89-1.23) when compared with ever users who did not use antidepressants 3 year before index date. In addition, no dose-response was observed by cumulative duration, cumulative dose and last daily dose. In secondary analysis, only current users of trazodone (aOR 1.26 [1.00-1.59]), imipramine (aOR 1.29 [1.03-1.62]), citalopram (aOR 1.70 [1.06-2.72]), duloxetine (aOR 2.41 [1.11-5.25]) and recent users of bupropion (aOR 2.87 [1.09-7.56]) significantly increased the risk of incident VHD. Conclusions Overall, we found antidepressants was not associated with risk of VHD. Nonetheless, it is rather remarkable that patients used trazodone, imipramine, citalopram, duloxetine or bupropion may increase 1.26 to 2.87-fold risk of incident VHD. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:37:08Z (GMT). No. of bitstreams: 1 ntu-103-R01451006-1.pdf: 1003307 bytes, checksum: b0cad441519d32365f9ee4fe5359e5d5 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 iii Abstract v 目錄 vii 表目錄 x 圖目錄 xi 縮寫表 xii 第1章 前言 1 第2章 文獻回顧 2 2.1 藥品引起心臟瓣膜疾病之文獻回顧 2 2.1.1藥品引起的心臟瓣膜疾病之定義、診斷與治療 2 2.1.2可疑藥品與致病機轉 3 2.1.3 藥品引起的心臟瓣膜疾病之發生率與風險因子 5 2.2 抗憂鬱藥品在臺灣之使用情況與適應症 6 2.3 抗憂鬱藥品與藥品引起的心臟瓣膜疾病之研究文獻 7 2.4 藥品引起的心臟瓣膜疾病之評估與資料庫編碼確效 8 第3章 研究目的 9 第4章 研究方法 10 4.1 資料庫編碼之確效-住院病人 10 4.1.1 資料來源與研究對象 10 4.1.2 心臟瓣膜疾病確效之定義 10 4.1.3 心臟超音波報告之選擇步驟 10 4.2 資料庫編碼之確效-門診病人 11 4.2.1 資料來源與研究對象 11 4.2.2 心臟瓣膜疾病確效之定義 11 4.2.3 心臟超音波報告之選擇步驟 12 4.3 嵌入型病例對照研究之研究設計 12 4.4 資料來源 12 4.4.1 臺灣全民健康保險研究資料庫 12 4.4.2 百萬人承保抽樣歸人檔 12 4.5 研究對象 13 4.5.1 病人族群與研究世代(cohort)之建立 13 4.5.2 病例組定義 13 4.5.3 對照組定義 14 4.6 抗憂鬱藥品之暴露變項 14 4.6.1 抗憂鬱藥品使用資料 14 4.6.2 抗憂鬱藥品使用時序之定義 14 4.6.3 抗憂鬱藥品累積用藥時間與劑量之定義 15 4.6.4 不同抗憂鬱藥品之分類 15 4.7 統計分析 16 4.7.1 描述性統計分析 16 4.7.2 條件式邏輯迴歸分析 16 4.7.3 統計軟體 16 第5章 研究結果 17 5.1心臟瓣膜疾病的資料庫編碼之確效-住院病人 17 5.2心臟瓣膜疾病的資料庫編碼之確效-門診病人 17 5.3病例組與對照組之建立 18 5.4 病人基本特性比較 18 5.5抗憂鬱藥品與心臟瓣膜疾病之風險相關性 19 5.5.1抗憂鬱藥品之使用時序 19 5.5.2抗憂鬱藥品之累積用藥時間 19 5.5.3抗憂鬱藥品之累積劑量及最後一劑每日劑量 19 5.5.4不同抗憂鬱藥品與心臟瓣膜疾病之相關性 20 5.6 建立心臟瓣膜疾病與其風險因子之統計模型 21 第6章 討論 22 6.1 心臟瓣膜疾病的資料庫編碼之確效-住院病人 22 6.2 心臟瓣膜疾病的資料庫編碼之確效-門診病人 23 6.3 研究族群之特性與藥品之使用 24 6.4 抗憂鬱藥品與心臟瓣膜疾病之相關性 24 6.4.1 抗憂鬱藥品之使用時序 24 6.4.2抗憂鬱藥品之累積時間、累積劑量及最後一劑每日劑量 25 6.4.3不同種類抗憂鬱藥品之使用時序 26 6.5 心臟瓣膜疾病之風險因子 28 6.6 研究特點與限制 29 6.6.1 研究之特色與優點 29 6.6.2 研究限制 30 第7章 結論 31 表 32 圖 48 參考文獻 51 | |
dc.language.iso | zh-TW | |
dc.title | 抗憂鬱藥品與心臟瓣膜疾病風險:嵌入型病例對照研究 | zh_TW |
dc.title | Antidepressants and valvular heart disease: A nested case-control study in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蕭斐元(Fei-Yuan Hsiao) | |
dc.contributor.oralexamcommittee | 劉言彬(Yen-Bin Liu),高淑芬(Shur-Fen Gau),王繼娟(Chi-Chuan Wang) | |
dc.subject.keyword | 抗憂鬱藥品,心臟瓣膜疾病,台灣全民健康保險資料庫,嵌入型病例對照研究, | zh_TW |
dc.subject.keyword | antidepressants,valvular heart disease,National Health Insurance Research Database (NHIRD),Taiwan,nested case-control study, | en |
dc.relation.page | 54 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 979.79 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。